HER2-targeted drug with pyrotinib for advanced HER2-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of two targeted medicines for people with advanced non-small cell lung cancer that has a specific HER2 gene change and has progressed after standard treatment. The goal is to see if the combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced non-small cell lung cancer that cannot be removed with surgery and has spread.
- Your cancer has a specific change in the HER2 gene called an exon 20 insertion mutation.
- You have already had standard treatments, including a platinum-based chemotherapy and an immunotherapy drug, and your cancer continued to grow or came back.
- You have at least one measurable tumor that can be tracked by scans.
- You have an ECOG performance status of 0 or 1, meaning you are fully active or able to do light activities.
- You must provide a sample of your tumor tissue for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies pyrotinib as a first (initial) anti-cancer treatment for advanced lung cancer that has specific HER2 changes. It aims to shrink tumors and control the cancer, especially in people whose test results show HER2 insertion mutation, point mutation, or amplification.
This trial tests whether taking pyrotinib continuously or intermittently can help people with HER2-positive advanced breast cancer that has spread. It is for those who have already received prior treatment for their advanced disease.
This trial studies whether adding pyrotinib after standard treatment helps prevent breast cancer from coming back in people with HER2-positive early-stage breast cancer. You may be eligible if you finished chemotherapy plus trastuzumab and still had signs of cancer in the tissue removed during surgery.
This trial tests whether a newer drug called dalpiciclib works better than chemotherapy when combined with two other anti-HER2 drugs (pyrotinib and trastuzumab) for advanced breast cancer that has spread. The goal is to find a treatment that works well with fewer side effects.
This study looks at how well the drug pyrotinib works in people with advanced breast cancer that has spread and tests positive for HER2. HER2 is a protein that can make cancer cells grow, and pyrotinib targets it. If you have this type of breast cancer, this study may show if the treatment helps you.
This trial tests a targeted drug called pyrotinib for women with HER2-positive breast cancer that hasn't spread far. It aims to see if adding this drug to standard treatment helps improve outcomes before and after surgery.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.